COVID-19 Induced Thrombotic Microangiopathy Profile
Use
Assessment of patients at high risk of COVID-19-associated thrombotic microangiopathy.
Special Instructions
Not provided.
Limitations
The von Willebrand Factor (vWF) Antigen test within this profile has been developed and its performance characteristics determined by Labcorp. However, it has not been cleared or approved by the Food and Drug Administration, and its use should be considered with this in mind. The test may not be suitable for detecting all instances of thrombotic microangiopathy, and results should be interpreted in the context of the patient's overall clinical presentation and other supporting tests.
Methodology
Other
Biomarkers
LOINC Codes
- 14804-9 - LDH SerPl L to P-cCnc
- 27816-8 - vWF Ag Act/Nor PPP IA
- 3209-4 - Fact VIII Act/Nor PPP
- 4532-8 - CH50 SerPl-aCnc
- 48065-7 - D Dimer PPP FEU-mCnc
- 53622-7 - vWF Cp Act/Nor PPP Chro
- 4532-8 - CH50 SerPl-aCnc
- 14804-9 - LDH SerPl L to P-cCnc
- 3209-4 - Fact VIII Act/Nor PPP
- 27816-8 - vWF Ag Act/Nor PPP IA
- 48065-7 - D Dimer PPP FEU-mCnc
- 53622-7 - vWF Cp Act/Nor PPP Chro
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Gel-barrier tube
Collection Instructions
Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate. Ensure complete filling to maintain proper blood to anticoagulant ratio. Mix immediately by gentle inversion at least six times. No discard tube required. Follow the correct order of tube collection. Centrifuge and carefully remove plasma using a plastic transfer pipette. Transfer plasma into a Labcorp PP transpak frozen purple tube with screw cap and freeze within four hours.
Storage Instructions
Frozen: Serum
Other tests from different labs that may be relevant